The portfolio maintains a cost advantage over competitors, priced within the second-cheapest fee quintile among peers.
Fidelity Select Biotechnology FBIOX
- NAV / 1-Day Return 20.98 / +0.77 %
- Total Assets 5.0 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.660%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.67%
- Turnover 52%
USD | NAV as of Oct 04, 2024 | 1-Day Return as of Oct 04, 2024, 10:28 PM GMT+0
Morningstar’s Analysis FBIOX
Will FBIOX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 11.43 | 572.6 Mil | Healthcare |
Amgen Inc | 9.05 | 453.6 Mil | Healthcare |
Krystal Biotech Inc | 7.31 | 366.4 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 5.20 | 260.4 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.41 | 220.7 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 3.63 | 181.8 Mil | Healthcare |
Gilead Sciences Inc | 2.61 | 130.9 Mil | Healthcare |
UCB SA | 1.97 | 98.9 Mil | Healthcare |
Zealand Pharma AS | 1.97 | 98.8 Mil | Healthcare |
Ascendis Pharma AS ADR | 1.82 | 91.3 Mil | Healthcare |